Introduction
It has been shown that the uptake of radioactive technetium (99Tcm) by affected joints is a useful clinical index of inflammation (Dick 1972) . The present study was designed to investigate the antiinflammatory properties of fenclofenac in rheumatoid arthritis using t9Tcm uptake as an objective assessment of inflammation.
addition, joint uptake of radioactive technetium (99Tcm) was carried out at each assessment (Dick 1972) . All assessments were performed by the same observer at the same time of day. At each visit blood samples were taken for routine hematological and biochemical monitoring and the patients were questioned regarding sideeffects.
Each patient attended on three occasions, at weekly intervals. During the first week their previous therapy was replaced with placebo, and during the second week with fenclofenac at a dose of 600 mg twice daily.
Results
In all, 18 patients completed the study. Four patients were withdrawn during the placebo period because of an exacerbation of their pain but no patients were withdrawn during the 
Materials and Methods
Twenty-two patients with definite or classical rheumatoid arthritis volunteered to participate in a single-blind study of fenclofenac and placebo in full knowledge of its aims and implications. These patients had a mean age of 53 years (range 27-63) and comprised 18 females and 4 males. All had active joint inflammation which had not been controlled on standard non-steroidal anti-rheumatic therapy. Patients who had no element of reversible disease or who had any contraindication to the use of fenclofenac were not admitted to the study. At each visit patients had full assessment of disease activity including grip strength, proximal interphalangeal joint circumference, articular index (Ritchie et al. 1968 ), pain index, and duration of morning stiffness (Lee et al. 1973 ). In 'Current address: Western District Teaching Hospitals Complex, Ward 7A, Gartnavel General Hospital, Glasgow fenclofenac period. Of the 18 patients completing both periods of therapy, 12 obtained marked clinical benefit from the active drug. The results of the assessments in these patients are summarized in Tables 1 and 2. In these it can be seen that the mean values of articular index, grip strength, ring size, pain score, morning stiffness duration and technetium uptake improved during the fenclofenac period as compared with both the placebo and pretreatment values. In the remaining 6 patients, less clinical benefit was observed, and the results for this group are shown in Table 3 . Im- (min) provement was noted in mean pain score and joint size but not in the other measured parameters. No clinically significant changes in laboratory values were observed in either group.
Few side-effects were encountered during the study and these were of a mild nature. Three patients complained of headache during the placebo week and two had mild gastrointestinal upset during the fenclofenac period.
Discussion
The current study demonstrates that in a group of patients in whom clear evidence of clinical benefit was achieved radioactive technetium studies have confirmed the anti-inflammatory activity of fenclofenac.
All of the patients selected for the study had active joint inflammation which was not adequately controlled by existing standard nonsteroidal anti-inflammatory agents. It is not surprising therefore to find a group of 6 patients who showed a less than optimal response to fenclofenac therapy and this is in agreement with studies with other non-steroidal anti-inflammatory agents carried out at this centre (Rooney et al. 1977) .
DISCUSSION
Dr H Berry (London) asked why it was thought that fenclofenac might be anti-inflammatory in its activity. There was a lot of evidence of its nonulcerogenic properties, but in conventional animal models it seemed to have a very low propensity as an anti-inflammatory agent. From much of the work carried out so far, there was very little to imply that it might be anti-inflammatory.
Dr Atkinson thought there was very good animal evidence to suggest that it was anti-inflammatory. It was effective in those models which normally detected clinically effective drugs and he did not agree with Dr Berry's statement.
Dr Goldberg asked Dr Berry if he considered that a reduction in joint size was evidence of antiinflammatory activity. If he did, then that had certainly been shown in Dr Goldberg's open study.
Dr Berry said he would certainly accept such a finding in controlled double-blind trials provided the patients had been on the drug for six months.
Dr P Fowler (Macclesfield) expressed his interest in diclofenac as it was a drug on which his own company was doing research. The differences in ulcerogenic potential of the two compounds, fenclofenac and diclofenac, had been shown quite clearly, but there was a very big difference in the metabolism of diclofenac in the rat and in man. There was an extensive enterohepatic circulation of the active ingredient which was a gastrotoxic drug in the rat, whereas in man it was only the metabolite, which was non-gastrotoxic, that was excreted in the bile. In the clinical situation therefore, the test that Dr Rainsford had been using was not relevant to this because of those differences.
Dr Rainsford said that the ulcer studies in stresssensitized rats had been done under acute conditions and in fact, in the time course of development, diclofenac was quite a potent gastric-ulcerogen, even at relatively low doses and the comments about alleged metabolic differences were questionable especially since little had been published about this. In that particular animal model, therefore, to say it was clinically irrelevant was rather inaccurate. In addition, he had investigated the effects of diclofenac in the pig, which was part of a parallel study that he had been doing. He said that the pig in many respects had similar gastrointestinal physiology to that of man and he had similarly found severe gastric lesions developing with the pure compound. This was in the non-stressed pig, and in fact he would be very grateful if Dr Fowler's company could give him some radioactive diclofenac so that he could find out if it had a similar metabolism to that in humans. At the moment they were unable to do so.
